Current antidepressants are clinically effective only after several weeks of administration. Here, we show that serotonin 4 (5-HT 4 ) agonists reduce immobility in the forced swimming test, displaying an antidepressant potential. Moreover, a 3 day regimen with such compounds modifies rat brain parameters considered to be key markers of antidepressant action, but that are observed only after 2-3 week treatments with classical molecules: desensitization of 5-HT 1A autoreceptors, increased tonus on hippocampal postsynaptic 5-HT 1A receptors, and enhanced phosphorylation of the CREB protein and neurogenesis in the hippocampus. In contrast, a 3 day treatment with the SSRI citalopram remains devoid of any effect on these parameters. Finally, a 3 day regimen with the 5-HT 4 agonist RS 67333 was sufficient to reduce both the hyperlocomotion induced by olfactory bulbectomy and the diminution of sucrose intake consecutive to a chronic mild stress. These findings point out 5-HT 4 receptor agonists as a putative class of antidepressants with a rapid onset of action.
INTRODUCTION
Considerable work has been devoted to the study of the mechanisms of antidepressant (AD) action, and it is now widely accepted that an increased central serotonergic (5-HT) neurotransmission constitutes a key therapeutic factor of such compounds (Blier and de Montigny, 1994, 1999) . This hypothesis has been strengthened by the successful use of selective serotonin reuptake inhibitors (SSRIs), the most commonly prescribed AD. Unfortunately for patients and clinicians, the mood improvement starts only after 3-6 weeks of AD treatment. Similarly, in animal behavioral models of depression, a period of 2-3 weeks of continuous administration is required to obtain an ''antidepressant-like'' effect. In keeping with these observations, a number of typical changes occur in the central 5-HT transmission of AD-administered rodents within the same time frame. These modifications include the desensitization of presynaptic 5-HT 1A autoreceptors (Blier and de Montigny, 1994, 1999; Mongeau et al., 1997; Blier, 2001; Artigas et al., 2002 ) and a strong increase of the inhibitory tonus mediated by postsynaptic 5-HT 1A receptors, particularly within the hippocampus (Haddjeri et al., 1998; Besson et al., 2000; Blier and Ward, 2003) . Longterm treatments with ADs also activate neurogenesis in the hippocampus (Malberg et al., 2000; Nakagawa et al., 2002a; Santarelli et al., 2003) . This requires the presence of 5-HT 1A receptors, and recent work indicates that activation of adult hippocampal neurogenesis may help mediate the beneficial action of ADs (Santarelli et al., 2003; Castré n, 2004) . Several studies have suggested that AD-induced neurogenesis is related to an elevation of the cAMP response element-binding protein (CREB) concentration in hippocampal neurons and, more specifically, to its phosphorylation into pCREB (Nibuya et al., 1996; Thome et al., 2000; Nakagawa et al., 2002a; Tiraboschi et al., 2004) .
Recently, we have reported that central 5-HT 4 receptors exert an excitatory control on rat dorsal raphe nucleus (DRN) 5-HT neuron firing activity (Lucas and Debonnel, 2002) . In agreement with several anatomical studies showing that the DRN is virtually devoid of 5-HT 4 mRNA and protein (Waeber et al., 1994; Vilaro et al., 1996) , we found that this control is indirect and involves 5-HT 4 receptors located in the medial prefrontal cortex (Lucas et al., 2005) . More promising data were obtained after short-and long-term treatments with 5-HT 4 agonists, showing that the 5-HT 4 -mediated positive control is already at its maximal level after 3 days and maintains the same amplitude after long-term (21 days) administration (Lucas et al., 2005) . Obviously, such findings raise the possibility that the stimulation of 5-HT 4 receptors may constitute a new way to achieve a rapid treatment for depression.
In this study, we first assessed the AD potential of 5-HT 4 agonists by using the forced swim test (FST) paradigm in rats. Although this behavioral model works already in subacute (30 min to 1 hr after injection) conditions and therefore does not match the above-mentioned chronic kinetics, it remains highly reliable in predicting the therapeutic potential of the tested compounds (Cryan et al., 2002) . Thereafter, we investigated whether the stimulation of 5-HT 4 receptors, after only 3 days of treatment with agonists, is able to elicit the same functional, morphological, and molecular changes as those induced by classical ADs, including (1) desensitization of DRN 5-HT 1A autoreceptors, (2) enhanced inhibitory tonus mediated by postsynaptic 5-HT 1A receptors in the hippocampus, (3) increased phosphorylation of CREB in hippocampal tissue, and (4) the induction of hippocampal neurogenesis. For this purpose, we used the selective 5-HT 4 agonists RS 67333 (Eglen et al., 1995) and prucalopride (Briejer et al., 2001) ; their effects were compared with those induced by a 3 day treatment with citalopram, considered to be the most selective SSRI (Sanchez and Hyttel, 1999) . To complete these experiments, we also used ''chronic'' behavioral models of depression, in which classical treatments require continuous administration for 2-3 weeks before any effect can be observed: the olfactory bulbectomy (OBX) paradigm (Song and Leonard, 2005) , chronic mild stress (CMS)-induced anhedonia (Jayatissa et al., 2006) , and the novelty-induced hypophagia test (Loiseau et al., 2006) .
RESULTS

Effects of 5-HT 4 Agonists and the SSRI Citalopram in the FST
The efficacy of the compounds used was first tested in the FST, which has proven to be a highly reliable predictor of AD potential (Cryan et al., 2002) . As shown in Figure 1A , both prucalopride and RS 67333 strongly reduced the time of immobility to a similar extent (around 50%): from 88.2 ± 7.2 s (control rats) to 43.4 ± 3.5 s and 42.7 ± 4.9 s, respectively. In contrast, citalopram induced a weaker effect, reducing the time of immobility by only 23% (62.6 ± 5.4 s). This effect was not statistically different from those of RS 67333 and prucalopride according to a global statistical assessment (i.e., Tukey's test performed after a one-way ANOVA taking into account all four groups), but, interestingly, the difference was significant when citalopram was compared only to both 5-HT 4 agonists (p < 0.05 versus either prucalopride or RS 67333). Concerning the influence on climbing, RS 67333 was more potent (C) Effect of RS 67333 (1.5 mg/kg, i.p.), prucalopride (2.5 mg/kg, i.p.), and citalopram (10 mg/kg, i.p.) on horizontal locomotion in activity chambers equipped with photoelectric cells to allow activity counts. Data are expressed as mean ± SEM of eight animals per group and are from an observation of 10 min duration. The different compounds were administered 30 min before testing. *p < 0.05, **p < 0.01 versus the vehicle, Tukey's test. than prucalopride and citalopram, as only its effect (+94%) reached statistical significance ( Figure 1B) . The FST has to be validated by also testing the influence of the compounds used on motor behavior, because an increase in motor activity could have also accounted for the observed results (Cryan et al., 2002; Haddjeri et al., 2004) . As shown in Figure 1C , neither RS 67333 nor citalopram had any effect on rat locomotion; however, prucalopride increased significantly this parameter (by 78%). We could not therefore exclude that the behavioral effects induced by prucalopride were at least in part related to a motor component.
Effect of a 3 Day Treatment with a 5-HT 4 Agonist on DRN 5-HT 1A Autoreceptor Sensitivity As previously reported (Sanchez et al., 2003) , the acute, i.v. administration of citalopram induced a dose-dependent inhibition of 5-HT neuronal firing rate in naive animals, with an ED 50 of 130 ± 30 mg/kg and an ED 100 of 280 mg/kg (Figure 2 ). In rats treated with the selective 5-HT 4 agonist RS 67333 (1.5 mg/kg/day), these values were shifted to the right, reaching 226 ± 26 and 430 mg/kg, respectively. A statistical comparison revealed that the slopes of the two dose-response curves were significantly different (À0.34 ± 0.03 versus -0.25 ± 0.02 for the vehicle and RS 67333 groups, respectively; F (1, 38) = 6.6, p = 0.014), confirming that the shift observed in the presence of RS 67333 was due to decreased sensitivity to citalopram. It is important to mention that this shift was observed with a similar amplitude in all neurons recorded from the RS 67333 group, their basal firing rate being either high (R2.0 Hz) or low (%1.0 Hz) (see Discussion). The acute inhibitory effect produced by an SSRI on DRN 5-HT neuronal activity results from increased extracellular levels of 5-HT, due to the blockade of its reuptake, and is selectively related to the stimulation of somatodendritic 5-HT 1A autoreceptors (Hajos et al., 1999) . The degree of inhibition induced by citalopram has therefore been used as a reliable index of their sensitivity (Arborelius et al., 2004; Sanchez et al., 2003) . It appears that a 3 day treatment with a 5-HT 4 receptor agonist is sufficient to desensitize 5-HT 1A autoreceptors in the DRN. The firing activity of dorsal hippocampus pyramidal neurons was then recorded in the CA 3 subfield, before and after systemic administration of the selective 5-HT 1A antagonist WAY 100635. This protocol has proved useful in revealing an increased tonic stimulation of inhibitory postsynaptic 5-HT 1A receptors, a common and selective trait for all AD treatments (Haddjeri et al., 1998; Besson et al., 2000; Blier and Ward, 2003) . As illustrated in Figure 3A , cumulative (100-500 mg/kg) i.v. injections of WAY 100635 had no effect on CA 3 pyramidal neurons in vehicle-treated animals, confirming that, in normal conditions of anesthesia, there is virtually no 5-HT 1A tone in this brain area (Haddjeri et al., 1998; Besson et al., 2000) . However, WAY 100635 had a dose-dependent excitatory effect in rats treated with either RS 67333 (1.5 mg/kg/day) or prucalopride (2.5 mg/kg/day) ( Figure 3A ). The effect was moderate in the prucalopride group, reaching statistical significance only after the highest cumulative i.v. dose of WAY 100635 (500 mg/kg), at 191% (±31%) of baseline. In the RS 67333 group, all three cumulative doses of 200, 300, and 500 mg/kg strongly increased the firing activity of CA 3 pyramidal neurons to 276% (±52%), 378% (±43%), and 445% (±60%) of basal values, respectively ( Figures 3A and 3B ). Three days of treatment with 5-HT 4 agonists was therefore sufficient to induce the apparition of a 5-HT 1A -mediated tonic inhibitory effect on CA 3 pyramidal neurons. In contrast, a 3 day treatment with citalopram did not affect the influence exerted by endogenous 5-HT on CA 3 5-HT 1A receptors. Indeed, as shown in Figure 3A , WAY 100635 induced only a marginal (not statistically significant) increase of CA 3 pyramidal neuron activity in the citalopram group, reaching around 135% of baseline after the highest cumulative dose of 500 mg/kg.
The decreased basal activity of CA3 pyramidal neurons after 3 days of treatment with 5-HT 4 agonists was confirmed by comparing the ejection currents of quisqualate required to perform the experiments. Indeed, as most hippocampal pyramidal neurons are not spontaneously active under chloral-hydrate anesthesia, a leak or a small ejection current (0 to À2 nA) of quisqualate (through the use of a multibarrelled electrode and microiontophoretic ''pumps,'' see Experimental Procedures) is necessary to Dose-response curves illustrating the effect of cumulative intravenous doses of citalopram on dorsal raphe nucleus (DRN) 5-HT neuron average (mean ± SEM) firing rate, expressed as percentage of basal activity, in rats treated with the selective 5-HT 4 agonist RS 67333 (1.5 mg/kg/ day, 3 days, n = 5) or its vehicle (n = 5). Single-cell extracellular recordings were performed in the DRN of chloral-hydrate anesthetized rats by using single-barrel glass microelectrodes, and 5-HT neurons were identified according to the classical criteria (see Experimental Procedures). RS 67333 was administered through the use of osmotic minipumps that were inserted subcutaneously in the region of the back. Recordings were performed with the minipumps still in place.
activate them within their physiological firing range of 10-15 Hz (Haddjeri and Blier, 1995; Haddjeri et al., 1998) . In the RS 67333-treated group, their excitability was reduced to such an extent that currents as high as -4 to -6 nA were required to obtain similar basal values ( Figure 3B) . Again, the effect was less prominent in the prucalopride group, as the required currents were between -2 and -4 nA (data not shown). Finally, the currents needed for quisqualate ejection in the citalopram group were similar to those used in control animals (0 to -2 nA, data not shown).
Involvement of Endogenous 5-HT and Hippocampal 5-HT 1A Receptors in the Effect of 5-HT 4 Agonists The most logical explanation for the above results would be that short-term treatments with 5-HT 4 agonists induced an increase of 5-HT release in the CA 3 subregion, which in turn resulted in an enhanced stimulation of postsynaptic 5-HT 1A receptors located on pyramidal neurons. This interpretation is consistent with our own previous findings showing that both acute and chronic (3 day) administration of these compounds augment DRN 5-HT neuronal firing activity (Lucas and Debonnel, 2002; Lucas et al., 2005) . It is also in keeping with observations from a single in vivo microdialysis study where acute systemic injection of preferential 5-HT 4 agonists increased hippocampal 5-HT efflux (Ge and Barnes, 1996) . To further address this possibility, two additional series of experiments were conducted. First, the role of endogenous 5-HT was assessed by using the same protocol as above in rats cotreated with RS 67333 (or its vehicle) and the 5-HT depleter parachlorophenylalanine (pCPA). In the vehicle group, pCPA had no effect per se on either CA 3 neuron firing activity or their response to WAY 100635 (data not shown; n = 4). However, as shown in Figure 3C , pCPA totally abolished the facilitatory action of WAY 100635 in rats treated with RS 67333 (n = 5). The ejection currents of quisqualate that are needed to activate CA 3 pyramidal neurons were, in this case, similar to those used in controls (0 to -2 nA; Figure 3C ). We then tested the ability of a local application of WAY 100635 directly into the CA 3 subfield through the use of microiontophoresis to modify the effect of a 5-HT 4 agonist. We chose not to use the previous protocol (i.e., chronic treatments), because, as shown above, the required quisqualate currents differ between the experimental groups. Even though all currents were balanced, it was not possible to exclude the possibility that the amount of quisqualate present in the vicinity of the electrode may have an influence on the quantity of WAY 100635 actually ejected and/or on its ability to act on pyramidal neurons. For this reason, we used prucalopride acutely in naive rats, at a dose known to induce both (A) Effect of cumulative intravenous doses of the selective 5-HT 1A antagonist WAY 100635 on the average (mean ± SEM) firing activity of hippocampal pyramidal neurons of the CA3 subfield in rats treated with the selective 5-HT 4 agonists RS 67333 (1.5 mg/kg/day, 3 days, n = 5) and prucalopride (2.5 mg/kg/day, 3 days, n = 5), with the SSRI citalopram (10 mg/kg/day, 3 days, n = 6), or with the vehicle (n = 5). Single-cell extracellular recordings were performed in the CA 3 region of chloral-hydrate-anesthetized rats by using multiple-barrel glass microelectrodes combined with microiontophoretic pumps (with the central barrel used for recordings). Pyramidal neurons were identified according to the classical criteria (see Experimental Procedures). All compounds were administered through the use of osmotic minipumps that were inserted subcutaneously in the region of the back. Recordings were performed with the minipumps still in place. *p < 0.05, **p < 0.01, ***p < 0.001 versus control, Tukey's test. ophenylalanine (pCPA; 150 mg/kg, i.p., once daily 72, 48, and 24 hr before the recordings). In this case, the ejection currents required for quisqualate were similar to those used in control animals. a significant and selectively 5-HT 4 -dependent augmentation of DRN 5-HT neuronal activity (1000 mg/kg, i.v.) (Lucas and Debonnel, 2002) . Of the 38 pyramidal neurons recorded, 21 were unaffected by prucalopride, whereas the remaining 17 (45% of total) were clearly inhibited, discharging at only 46% (±5.6%) of predrug values ( Figure 4 ). This inhibition was totally reversed by the microiontophoretic application of WAY 100635 (1 nA), devoid of any effect by itself ( Figures 4A and 4B ). The involvement of 5-HT 4 receptors in the action of prucalopride was confirmed, as it was abolished by systemic administration of the selective 5-HT 4 antagonist GR 125487 (1000 mg/kg, i.v.; Figures 4C and 4D ).
Effect of 3 Day Treatments with 5-HT 4 Agonists and the SSRI Citalopram on CREB Phosphorylation in the Hippocampus
Having confirmed a critical role for DRN-hippocampus 5-HT transmission in mediating the effects of 5-HT 4 agonists, the next step was to determine whether the observed changes in 5-HT neurotransmission were accompanied by a modification in molecular dynamics downstream of receptor activation. It has been previously shown that ADs that enhance 5-HT extracellular levels, such as SSRIs, promote cAMP signaling in hippocampal neurons and increase CREB activation-an effect that becomes evident only after 2 weeks of chronic administration (Nibuya et al., 1996; Thome et al., 2000; Tiraboschi et al., 2004) . Thus, we were interested in finding out whether 5-HT 4 agonists were able to produce a faster activation of this transcription factor. CREB activation was measured by immunoblot using state-specific antibodies that label its phosphorylated active form. In keeping with previous reports (Pliakas et al., 2001) , pCREB appeared as an immunoreactive band at 46 kDa. A band corresponding to the total amount of transcription factor present in the sample was observed at similar molecular weight ( Figure 5 ). While maintaining total CREB levels unchanged (optic density: control 0.40 ± 0.03, prucalopride 0.32 ± 0.02, RS 67333 0.39 ± 0.03, citalopram 0.37 ± 0.02; Figure 5 ), a 3 day treatment with RS 67333 and prucalopride enhanced pCREB immunoreactivity. Corresponding pCREB/CREB ratios for different treatments are shown ( Figure 5 ) and indicate that only exposure to RS 67333 significantly enhanced the proportion of CREB in its phosphorylated state within the hippocampus. Indeed, the mean values of ratios were 0.18 ± 0.01, 0.30 ± 0.07, and 0.37 ± 0.07 in the control, prucalopride, and RS 67333 groups, respectively. The increase observed in RS 67333-treated animals (+105%) was statistically significant (p < 0.05, Dunnett's test after significant one-way ANOVA), whereas the +66% effect found in the prucalopride group did not reach statistical significance (p = 0.06). Citalopram in contrast left pCREB values unchanged.
Effect of a 3 Day Treatment with Either RS 67333 or Citalopram on Hippocampal Neurogenesis
Classical ADs (and especially SSRIs) promote adult neurogenesis in the hippocampus (Malberg et al., 2000; Duman et al., 2001; Nestler et al., 2002; Castré n, 2004) . Increased neurogenesis occurs predominantly in the subgranular zone (SGZ) of the dentate gyrus (Malberg et al., 2000; Nakagawa et al., 2002a; Santarelli et al., 2003) and requires at least 2 or 3 weeks of chronic treatment (Malberg et al., 2000; Nakagawa et al., 2002a; Santarelli et al., 2003) . Remarkably, a 3 day treatment with RS 67333 significantly enhanced the number of bromodeoxyuridine (BrdU)-positive cells in the SGZ (Figure 6 ). In the RS 67333 group, the stereological count indicates that the volumetric density of BrdU-positive cells (per mm 3 ) increased to 128% of vehicle values (19,120 ± 723 versus 14,955 ± 699; p < 0.01, Tukey's test; see inset in Figure 6 ). Detailed morphological analysis of the histological sections revealed that these cells were grouped in clusters of six to ten clones following the RS 67333 treatment, suggesting an acute induction of mitotic activity ( Figure 6A ). Such clusters of BrdU-positive cells were never observed in the vehicle group ( Figure 6C ) and were sparse in the citalopram group ( Figure 6B ). In comparison to RS 67333, a 3 day treatment with citalopram had no effect on the number of BrdU-positive cells (15,146 ± 753, hence 101% of control values; Tukey's test, n.s; inset in Figure 6 ). The mean coefficient of error (Luk and Sadikot, 2001 ) of BrdU-IR granule layer cell counts was 0.09 ± 0.005 (n = 12).
Effect of Chronic Treatments with Either RS 67333 or Citalopram on the Hyperlocomotion Induced by Olfactory Bulbectomy
As previously reported (Cryan et al., 1999) , 14 days after surgery, olfactory bulbectomized (OBX) rats displayed a significant increase of locomotor activity with respect to sham-operated animals ( Figure 7A ). Results were expressed as the distance covered over a 5 min period and were found to be 51% higher in the OBX-vehicle group than those of the sham group (3730 ± 400 cm versus 2466 ± 328 cm, p < 0.05, Tukey's test). More interestingly, a 3 day treatment with RS 67333 strongly reduced this augmentation, by more than one-half. As shown in Figure 7A , the distance covered in the OBX-RS 67333 group was 3155 ± 241 cm, reaching 24% above sham values. This result was not statistically different from that obtained in OBX-vehicle animals (Tukey's test, n.s.), but there was also no difference (Tukey's test, n.s.) with sham-operated rats, indicating a marginal increase only. Effect of the selective 5-HT 4 agonists RS 67333 (1.5 mg/kg/day, 3 days) and prucalopride (2.5 mg/kg/day, 3 days) and of the SSRI citalopram (10 mg/kg/day, 3 days) on the activation of CREB in hippocampal tissue, assessed by measuring phosphoCREB (pCREB) immunoreactivity. CREB phosphorylation was normalized according to the amount of protein present in each sample by expressing the data as a ratio of pCREB over total CREB immunoreactivity (see Experimental Procedures for more details). Results represent mean ± SEM for the number of experiments indicated for each treatment. Inset shows representative examples of pCREB immunoreactivity for different treatment conditions indicated on the histogram. All compounds were administered through the use of osmotic minipumps that were inserted subcutaneously in the region of the back. *p < 0.05 versus vehicle, Tukey's test. By contrast, the OBX-citalopram group displayed values very similar to those found in the OBX-vehicle group (3870 ± 345) and was significantly different from the sham (+57%; p < 0.05, Tukey's test).
To confirm the validity of our experimental conditions, animals were also tested after 14 days of treatment with the compounds used. Indeed, it is well established that, after such a period of chronic administration, SSRIs are able to reduce the effect of OBX on locomotion (Song and Leonard, 2005) . As illustrated in Figure 7B , the values found in OBX-citalopram rats were only 18% above those of their sham-operated counterparts and were not significantly different from them (Tukey's test, n.s.). In addition, further confirming the promising results observed after 3 days, a 14 day treatment with RS 67333 totally abolished the hyperlocomotor effect of the bulbectomy, with a distance covered very similar to that of sham-operated animals (2649 ± 326 and 2619 ± 248 cm, respectively) and statistically different from that of OBX-vehicle rats (p < 0.05, Tukey's test).
Effect of Chronic Treatments with Either RS 67333 or Citalopram on the Reduction of Sucrose Intake Induced by Chronic Mild Stress As shown in Figure 8 , 2 weeks of initial exposure to CMS resulted in a strong reduction of sucrose intake. When Effect of RS 67333 (1.5 mg/kg/day) and citalopram (10 mg/kg/day) on the locomotor activity in olfactory bulbectomized (OBX) rats. The OBX surgery was performed by using a suction strategy (see Experimental Procedures for more details), and animals were allowed to recover for a period of 11 days. RS 67333 and citalopram were then administered through the use of osmotic minipumps that were inserted subcutaneously in the region of the back, and locomotion was measured in an open-field apparatus both 3 days (A) and 14 days (B) after the insertion. Effect of repeated administrations of RS 67333 (0.75 mg/kg/day) and citalopram (10 mg/kg/day) on sucrose intake (mean ±SEM) in the chronic mild stress (CMS) model. Rats were separated into two groups, one undergoing a CMS protocol optimized in our laboratory (see Experimental Procedures for more details), while the other one was left unchallenged. After 2 weeks of initial exposure to CMS, the stressed group (n = 40) was subdivided into three subgroups: RS 67333 (n = 16), citalopram (n = 16), and vehicle (n = 8). Pharmacological treatments started on day 1, and consisted of one daily i.p. injection in the morning. The stress procedure was continued thereafter, during the entire period of treatment. Panel (A) illustrates the effect of RS 67333 (n = 9) and citalopram (n = 8) in ''responders,'' i.e., rats in which RS 67333 and citalopram had a significant effect on sucrose intake (see Results for more details). ''Nonresponders'' are shown in panel (B). For each time point, *p < 0.05, **p < 0.01, and ***p < 0.001 versus the stressed vehicle group, Tukey's test. The nonstressed vehicle group is composed of ten animals.
comparing the values between challenged (vehicle group) and unchallenged (nonstressed vehicle group) animals on day À3 (i.e., 3 days before starting chronic treatments), the amplitude of decrease was revealed to be higher than 50% (6.7 ± 0.05 versus 14.3 ± 0.88 g of sucrose consumed). A chronic treatment with either RS 67333 (0.75 mg/kg/day) or citalopram (10 mg/kg/day) induced a reversion of this effect in about 50% of the stressed animals (''responders;'' Figure 8A ), whereas the remaining ones did not respond (''nonresponders;'' Figure 8B ). Such a bimodal distribution has already been observed in our experimental conditions by using escitalopram, the S enantiomer of citalopram (Jayatissa et al., 2006 ). It appears to be a stable, highly reproducible phenomenon, independent from the dose of SSRI administered (Jayatissa et al., 2006) . Together with the present data, this suggests that the existence of two populations of rats (one-half responding to a putative AD, while the other one will not) is a general feature of our CMS protocol and that it is not related to the use of a specific type of molecule. Also, citalopram and RS 67333 had no influence on their own on sucrose intake in nonstressed animals (data not shown, n = 10 for each).
Even more interestingly, our results indicate that the effect of RS 67333 had a much more rapid onset of action than citalopram. Thus, after only 3 days of treatment, sucrose intake in the RS 67333 group was already significantly higher than in the vehicle (77% versus 51% of nonstressed animal values at the same time point, p < 0.05, Tukey's test after significant one-way ANOVA). By contrast, sucrose intakes in citalopram-and vehicle-treated rats were very similar at that time (52% versus 51%, Tukey's test, n.s.). On day 10 of treatment, the citalopram group was still not statistically different from the vehicle group (Tukey's test, p = 0.12), even though sucrose intake was substantially enhanced (74% versus 47% of nonstressed animal values). On the other hand, there were no more significant differences between RS 67333-administered and unchallenged rats (90% versus 100%). Actually, a more detailed examination of Figure 8A reveals that sucrose intake in the RS 67333 group was somewhat lower than in the two other groups of stressed animals (5.6 versus 6.7-7.1 g) on day À3, i.e., before any pharmacological treatment had been started. A very similar difference of around 1 g was still observable on day 10, this time with respect to unchallenged animals (13.4 versus 14.8 g). These comparisons strongly suggest that a 10 day treatment with RS 67333 was sufficient to fully reverse the inhibitory effect of CMS on reward. By contrast, citalopram induced a comparable, full reversion of CMS influence only after 24 days of continuous administration ( Figure 8A ).
Effect of RS 67333 and the SSRI Fluoxetine in the Novelty-Induced Hypophagia Test
In this test, we used an acute injection of diazepam (2 mg/ kg, i.p.), a typical anxiolytic of the benzodiazepine class, as a positive control. Indeed, as previously reported (Loiseau et al., 2006) , this treatment induced a strong increase of food consumption in food-deprived animals (see Figure S1 in the Supplemental Data available with this article online). By contrast, neither fluoxetine (10 mg/ kg/day, 14 days) nor RS 67333 (1.5 mg/kg/day, 3 days) modified this parameter in our experimental conditions ( Figure S1 ). It appears therefore that, similarly to SSRIs, RS 67333 has poor influence on anxiety-related components of ''depression-like'' behaviors in Sprague-Dawley rats (see Discussion for details).
DISCUSSION
The first result of this study indicates that 5-HT 4 agonists have properties common to classical ADs in the FST, suggesting that they may have a potential interest for the treatment of depression. The reduction of immobility time that we found in this test for both RS 67333 and prucalopride (À50%; Figure 1 ) was of higher amplitude than the one typically observed 30-60 min after single injections of SSRIs (around -25%, not significant in all the studies) (Cryan et al., 2002; Haddjeri et al., 2004 ; present study). The effect induced by prucalopride, however, was also paralleled by an increase of motor activity. It is possible that the low affinity displayed by this compound for dopamine-D 4 receptors (Briejer et al., 2001 ) may account for this result, because even a weak stimulation of D 4 receptors has been reported to facilitate locomotion (Nayak and Cassaday, 2003) . Whatever its exact causes, this nonspecific action of prucalopride prompted us to not use this drug at a dose higher than 2.5 mg/kg, even if it is likely not maximal with respect to 5-HT 4 receptor stimulation. Indeed, prucalopride can induce robust central effects at a dose as high as 5 mg/kg, i.p., in a manner that appears to be still selective for 5-HT 4 receptors (i.e., blocked by selective 5-HT 4 antagonists) (Porras et al., 2002) . This result on locomotion also constitutes the main reason for the present study to be more focused on the use of RS 67333; prucalopride has been used alone only when necessary and if the 5-HT 4 dependency of the effect to be produced had been previously established (see below).
Most importantly, our results indicate that electrophysiological, molecular, morphological, and behavioral changes that have previously been specifically linked to long-term treatment with SSRIs are already present after only 3 days when using 5-HT 4 agonists. Consistent with the facilitatory action displayed by the latter, at the same dose regimen, on DRN 5-HT neuron firing rate (Lucas et al., 2005) , we found that the DRN-hippocampus 5-HT transmission was deeply modified by 5-HT 4 receptor activation. The shift to the right in the ability of acutely administered citalopram to inhibit 5-HT neuron firing rate (Figure 2) clearly suggests a decreased sensitivity of somatodendritic 5-HT 1A autoreceptors. It could still be argued that this shift only resulted from the arithmetic sum of two opposite influences, namely an inhibition caused by citalopram versus the facilitatory effect of the 5-HT 4 agonist. However, this effect was observed in all the neurons recorded (see Results). We have previously shown that a subpopulation, representing about one-half of DRN 5-HT neurons and discharging at a low (%1.0 Hz) basal frequency, is not sensitive to 5-HT 4 receptor stimulation (Lucas and Debonnel, 2002 ). It appears therefore that the reduced sensitivity to citalopram observed in all neurons was related to a ''true'' desensitization of 5-HT 1A autoreceptors. This strongly suggests that 5-HT extracellular levels were enhanced in the DRN after a 3 day treatment with RS 67333, as already proposed to explain the desensitization induced by SSRIs (Blier and de Montigny, 1999; Artigas et al., 2002) , which is known to progress gradually, being observable only after 2-3 weeks (Blier and de Montigny, 1994; El Mansari et al., 2005) . The more rapid desensitization observed with RS 67333 may be due to the different characteristics of the mechanisms involved: rather than a passive elevation of 5-HT extracellular levels consequent to the blockade of 5-HT reuptake sites and related to a slow diffusion within extracellular space, the activation of 5-HT neuronal firing rate elicited by 5-HT 4 agonists should facilitate a true, active release of 5-HT within the DRN.
This possibility is also consistent with our conclusion that 5-HT release was enhanced in projection areas, more particularly the dorsal hippocampus, after a 3 day treatment with 5-HT 4 agonists. This enhancement was unveiled by the manifestation of an inhibitory tonus, mediated by endogenous 5-HT through the stimulation of postsynaptic 5-HT 1A receptors (Figure 3) . Such an effect has already been observed with numerous classical AD treatments, but only after 2-3 weeks of sustained administration (Haddjeri et al., 1998; Besson et al., 2000; El Mansari et al., 2005) . In agreement with these previous studies, our results indicate that citalopram was ineffective when administered for 3 days. Moreover, in the case of RS 67333, the inhibitory tonus appeared to be stronger than that induced by a 21 day treatment with SSRIs: the selective 5-HT 1A antagonist WAY 100635 was able to increase CA 3 pyramidal neuron activity up to 440% of predrug values (Figure 3 ), whereas this disinhibition has been reported to reach a maximum of 200% after 3 weeks of treatment with the SSRI paroxetine or other classical AD treatments (Haddjeri et al., 1998) . The effect of prucalopride, on the other hand, was more modest, as a high cumulative dose of WAY 100635 was needed to unveil the existence of the 5-HT 1A -mediated tonus. The difference of amplitude between the effects of the two 5-HT 4 agonists is in agreement with their respective action on DRN 5-HT neuron mean firing rate: prucalopride enhanced this parameter by about 40%-45%, whereas the effect of RS 67333 reached 70% (Lucas et al., 2005) . It is therefore possible that the augmentation of 5-HT release induced by prucalopride in the hippocampus was less important than that elicited by RS 67333. It is of interest to be reminded that the dose of prucalopride used for these chronic treatments is relatively low (see above). In contrast with these modest short-term chronic effects, the acute injection of 1000 mg/kg, i.v., prucalopride was able to inhibit the activity of CA 3 pyramidal neurons by almost 50% (Figure 4 ) (in 45% of the cases; see the Supplemental Discussion, Part 1 for a detailed discussion on this latter point). We already knew (see Results) that this acute dose of prucalopride produces a strong increase of DRN 5-HT neuronal activity (around 100%), which is totally blocked by 5-HT 4 antagonists. Thus, because we did not know about the i.v. dose of RS 67333 required to obtain a similar effect, in this particular case, we decided to conduct the experiments with prucalopride, even though RS 67333 was preferred in the rest of the study (see our statement concerning the two drugs, above). These findings on 5-HT 1A neurotransmission are of high importance in a therapeutic perspective-an increased 5-HT 1A -mediated inhibition of hippocampal cells being considered a crucial step to obtain the beneficial effects of ADs such as SSRIs (Haddjeri et al., 1998; Santarelli et al., 2003; Castré n, 2004) .
In line with this statement, we found that both prucalopride and RS 67333 were able, after only 3 days of chronic administration, to enhance the pCREB/CREB ratio in hippocampal tissue. Such an increase has also been reported to constitute a specific marker of AD action in rat brain (Nibuya et al., 1996; Thome et al., 2000; Nakagawa et al., 2002a; Tiraboschi et al., 2004) but, again, has never been observed before 1.5-2 weeks of treatment (Nibuya et al., 1996) , as confirmed by the lack of effect of citalopram observed in the present study. The effect of RS 67333 was stronger than that of prucalopride, paralleling electrophysiological results, but more importantly, it was also of higher amplitude (+105%; Figure 5 ) than the previously reported increase induced by long-term SSRI treatment (+20%-30%) (Tiraboschi et al., 2004) . The possibility that this higher amplitude is due to a dual action of 5-HT 4 agonists cannot be excluded, as a number of data suggest that the stimulation of 5-HT 4 receptors located on pyramidal neurons may activate CREB (Duman, 1998) . This direct effect could amplify the ''indirect 5-HT 1A agonist'' effect of 5-HT 4 agonists. Indeed, the hypothesis that hippocampal 5-HT 1A and 5-HT 4 receptors exert such a synergetic, facilitatory control on CREB activation has already been proposed (Duman, 1998) . Several studies have shown that the proneurogenetic action of SSRIs is directly related to their ability to phosphorylate CREB (Nakagawa et al., 2002a (Nakagawa et al., , 2002b and that increased neurogenesis is crucial for the AD potential of these compounds (Santarelli et al., 2003) . We therefore tested whether a 3 day treatment with RS 67333, the most active of the 5-HT 4 agonists used in electrophysiological and molecular experiments, was also able to facilitate neurogenesis in the hippocampus. The results shown in Figure 6 clearly confirm the ability of such a treatment to enhance cell division and proliferation in the SGZ. The increase observed in the stereological count of BrdU-positive cells (+28%) was very similar to that previously reported after a 14 day treatment with the SSRI fluoxetine (+35%) (Malberg et al., 2000) . As opposed to RS 67333, citalopram remained totally inactive after 3 days of continuous administration. To our knowledge, this is the first time that a compound known to facilitate 5-HT transmission has been shown to activate adult hippocampal neurogenesis so rapidly. So far, the quickest effect reported was 11 days for fluoxetine, which was inactive at 5 days (Santarelli et al., 2003) ; with other ADs, neurogenesis occurred only after 2-3 weeks (Malberg et al., 2000; Castré n, 2004) . A short paragraph on the possible conceptual consequences of this result is proposed in the Supplemental Discussion, Part 2.
Finally, the fast-acting AD potential of 5-HT 4 agonists was further confirmed by several ''chronic'' behavioral models of depression. In the OBX paradigm, lesioned animals display a higher spontaneous locomotor activity than their sham counterparts when placed in an open field in conditions of high illumination. This effect is believed to be due to a deficit of habituation in a stressful environment and is reversed by long-term (2-3 weeks), but not acute, treatments with SSRIs (Song and Leonard, 2005) . Accordingly, our results show that the continuous administration of citalopram to OBX rats, totally ineffective after 3 days, induces an important reduction of the locomotor hyperactivity after 14 days (Figure 7) . However, and more importantly, they also show that a 3 day treatment with RS 67333 is already able to counteract the effect of bulbectomy, with an efficacy comparable to that of 14 days of citalopram. This quicker onset of action was further confirmed by the fact that, after 14 days of RS 67333, the hyperlocomotion was totally abolished. The kinetics observed in the CMS studies were very similar. This test is thought to constitute a model for the anhedonic component of depression, and SSRIs have proved effective to progressively suppress the adverse effect of CMS on sucrose intake (Jayatissa et al., 2006) . In keeping with the present results (Figure 8 ), these molecules induce a full reversion only after 2 or 3 weeks of chronic administration (Jayatissa et al., 2006) . In the same conditions, RS 67333 was already able to counteract the influence of CMS after 3 days, and the reversion appeared to be total after 1 week (Figure 8 ). That the kinetics of OBX and CMS tests were so similar is even more remarkable when considering that the dose of RS 67333 selected for the latter was only 0.75 mg/ kg/day. Indeed (see Experimental Procedures), we chose to administer the animals with half the dose of RS 67333 used in the rest of the study. The fact that RS 67333 was still effective suggests that the potential AD properties of 5-HT 4 agonists may be quite strong. Once again, the 5-HT 4 agonist appeared to be four to five times more rapid than the SSRI to display antidepressant-like properties, in true, ''chronic'' behavioral models of depression. The picture was different when considering the results of the novelty-induced hypophagia test. Neither the typical SSRI fluoxetine (14 days) nor RS 67333 (3 days) were able to increase the amount of food consumed by rats in a novel environment, as opposed to the anxiolytic diazepam. However, whereas OBX and CMS are believed to represent ''affective'' components of depression (i.e., habituation to stressful stimuli and ability to cope therewith and anhedonia; see above), novelty-induced hypophagia is considered to be more an ''anxiety-depression'' model (David et al., 2007) , or even for others, a test of anxiety as such (Bodnoff et al., 1989) . Moreover, depending on the strain and/or the species studied, it can be affected by SSRIs independently from changes in central 5-HT function or hippocampal neurogenesis . Conversely, the effects of SSRIs in both the OBX and CMS models appear to be paralleled by an increase of mitotic activity within the hippocampus (Jayatissa et al., 2006; Jaako-Movits et al., 2006) . It can therefore not be excluded that, in Sprague-Dawley rats, noveltyinduced hypophagia is poorly sensitive to an enhanced 5-HT neurotransmission. Alternatively, it is also possible that both SSRIs and 5-HT 4 agonists are less effective on ''anxiety-related'' components of depression in this rat strain.
Overall, the results presented here show a clear potential for 5-HT 4 agonists as putative antidepressants with a rapid onset of action. According to the different experimental models studied, they may act four to seven times more rapidly than classical ADs and possibly with greater efficacy. Presently, RS 67333 and prucalopride are virtually the only available selective 5-HT 4 agonists that are able to cross the blood-brain barrier; we hope that this study may contribute to the development of new compounds, so that clinical trials can be conducted in the near future.
EXPERIMENTAL PROCEDURES Animals
Experiments were carried out in male Sprague-Dawley (Charles River, St-Constant, Qué bec, Canada, and Harlan, Gannat, France) or Wistar (Taconic, Denmark) rats, weighing 250-300 g and kept under standard laboratory conditions (12:12 light-dark cycle with free access to food and water). Different rats were used for the FST and the locomotor activity responses. For CMS experiments, the animals were singly housed, except when grouping was applied as a stress parameter. All animals were handled according to the guidelines approved by the faculty ethical committees of our institutions.
Drugs and Chemicals
The following compounds were used: GR 125487 sulphamate, prucalopride monohydrochloride, citalopram hydrobromide (gifts from Glaxo, Janssen, and Lundbeck laboratories, respectively), RS 67333 hydrochloride (Tocris Cookson Inc., Ellisville, MO), WAY 100635 hydrochloride (Research Biochemicals, Natick, MA), pCPA methyl ester hydrochloride, BrdU (Sigma-Aldrich Canada, Oakville, Ontario, Canada). BrdU was diluted in Tris-buffered saline (0.1 M in NaCl 0.9% [ph 7.6]), and the other compounds in distilled water. All drug dosages refer to the free base. For chronic treatments, except in the case of CMS experiments (see below), prucalopride (2.5 mg/kg/day), RS 67333 (1.5 mg/kg/day), citalopram (10 mg/kg/day), or the vehicle were delivered through osmotic minipumps (Alza, Palo Alto, CA) inserted subcutaneously in the region of the back under short-duration (%5 min) halothane anesthesia. The 5-HT depleter pCPA was administered once daily at the dose of 150 mg/kg, i.p., 72, 48, and 24 hr before the recordings. BrdU treatments consisted of two administrations per day (50 mg/kg, i.p. each, 8 hr interval), starting from the day of minipump insertion until day 2 postsurgery.
For CMS studies, drugs were administered i.p. daily in the morning. Also, to lower the cost of these experiments (related to the high number of animals used and to the frequency of injections), we chose to reduce the dose of RS 67333 administered to 0.75 mg/kg/day.
Extracellular Recordings of DRN 5-HT Neurons
Recordings were performed using single-barreled glass micropipettes, according to a procedure routinely performed in our laboratory (Lucas and Debonnel, 2002) .
Microiontophoresis and Extracellular
Recordings from Hippocampal CA 3 Pyramidal Neurons Recording and microiontophoresis were performed with five-barreled glass micropipettes, according to a procedure routinely performed in our laboratory (Lucas et al., 2005) . The side barrels contained quisqualate (1.5 mM in 200 mM NaCl [pH 8]), WAY 100635 (15 mM in 200 mM NaCl [pH 4]), and 2 M NaCl used for automatic current balancing.
Assessment of CREB and pCREB Immunoreactivities
Following decapitation (performed under halothane anesthesia), rat brains were dissected on ice-cold artificial cerebrospinal fluid (125 mM NaCl, 2.4 mM KCl, 0.83 mM MgCl 2 , 1.1 mM CaCl 2 , 0.5 mM KH 2 PO 4 , 0.5 mM NaSO 4 , 27 mM NaHCO 3 , 10 mM glucose, 10 mM HEPES [pH 7.4] ). Isolated hippocampi (1-2 mg wet tissue/100 ml) were homogenized in solubilization buffer containing 20 mM HEPES (pH 7.9), 0.4 M NaCl, 20% (v/v) glycerol, 1% (v/v) Nonidet P-40, 5 mM MgCl 2 , 0.5 mM EDTA, 0.1 mM EGTA, 1 mM phenylmethanesulfonyl fluoride, 1 mM okadaic acid, 5 mM dithiothreitol, 5 mg/ml leupeptin, 5 mg/ml soybean trypsin inhibitor, and 10 mg/ml benzamidine by means of a dounce homogenator. Homogenates were then adjusted to a concentration of 2 mg protein/ml and incubated on ice for 30 min, after which they were centrifuged for additional 30 min at 15,000 3 g. The supernatant was discarded, and SDS sample buffer was added to the pellet for posterior immunoblot analysis. For detection of CREB activation, samples were sonicated and then boiled for 5 min before loading for SDS-PAGE that was performed as previously described (Piñ eyro et al., 2001 ) using a 4% stacking gel and 10% separating gel. Proteins resolved in SDS-PAGE were then transferred from gels onto nitrocellulose (50 mA, 16 hr, Bio-Rad Mini-Trans Blot apparatus) and pCREB detected by probing membranes with anti-pCREB monoclonal antibody (1B6) from Cell Signaling Technology (1:1000). Total CREB contents were determined after stripping by using 1:1000 dilution of anti-CREB antibody (Cell Signaling Technology). Secondary antimouse (1:5000; Sigma) or antirabbit (1:40000; Amersham) horseradish-conjugated antibodies and enhanced chemiluminescence detection reagents (NEN Life Science Products) were used to reveal blotted proteins. Relative intensities of the labeled bands were analyzed by densitometric scanning using MCID (Imaging Research Inc), and CREB-activation was expressed as the ratio between pCREB and total CREB present in each sample. For each drug (citalopram, prucalopride, and RS 67333) , experiments were conducted in parallel with three vehicle-treated animals (i.e., the ''-'' immunoblots shown in Figure 5 ). Since values of the pCREB/CREB ratio did not differ statistically between these different controls, they were regrouped to form the vehicle group of the histogram.
Measurement of Hippocampal Neurogenesis
Animals were deeply anesthetized by using an overdose of sodium pentobarbital (75 mg/kg, i.p) and perfused transcardially with an initial wash of heparinized 0.9% saline (50-100 ml, 4 C), followed by 4% paraformaldehyde in phosphate buffer (300 ml, 0.1 M [pH 7.4], 4 C).
Brains were immersed for 48 hr in 30% phosphate-buffered sucrose solution (pH 7.4) and then cut in the coronal plane at 50 mm on a sliding freezing microtome. Free-floating sections were collected in phosphate-buffered saline (PBS, 0.1 M [pH 7.4] ) as separate sets so that each set contained every sixth serial section. Selected adjacent freefloating sections were processed for double-labeling immunohistochemistry for BrdU (5 0 -bromodeoxyuridine) and Nissl staining by using minor modifications of a previously published method (Soriano and Del Rio, 1991; Sadikot and Sasseville, 1997) . Briefly, sections were incubated in 0.5% sodium borohydride dissolved in PBS for 20 min and rinsed twice in PBS. They were then incubated for 30 min in 1% triton X-100 in PBS containing 0.03% hydrogen peroxide, followed by 1% dimethlysulfoxide (DMSO) in PBS for 10 min. Sections were immersed in 2 N HCl in PBS for 60 min and then neutralized by rinsing in sodium borate buffer (0.1 M [pH 8.5]) for 5 min. After brief washes in PBS (three times, 5 min each), they were preincubated in PBS containing 10% bovine serum albumin (BSA) and 0.3% triton X-100 for 30 min, briefly rinsed in PBS, and then incubated for 14-16 hr in PBS containing anti-BrdU antibody (1:40, Becton Dickinson, San Jose, CA) and 2% BSA (4 C). After three brief rinses in PBS, sections were incubated in PBS containing secondary antibody (biotinylated antimouse IgG, 1:200, Vector, Burlinghame, CA) and 2% BSA. Following three brief rinses in PBS, sections were incubated for 1 hr in avidin-biotin complex (ABC, 1%, in PBS, Vector). Next, sections were briefly rinsed three times in PBS, and the immunohistochemical reaction product was revealed by incubating for 7-10 min in a solution containing 0.37 mg nickel ammonium sulfate, 25 mg 3.3 0 -diaminobenzidine tetrahydrochloride (DAB), and 2 ml of hydrogen peroxide (30%) dissolved in 100 ml of Tris buffer (0.05 M [pH 7.6]). This nickel-enhanced DABbased chromogen yields a blue-black reaction product. Sections were thoroughly rinsed in PBS and then mounted out of distilled water on glass slides, air-dried, dehydrated in a 80% ethanol solution overnight, then proceed with Cresyl Violet (CV) staining, cleared in Xylene Substitute (Shandon, Pittsburgh, PA), and coverslipped with Permount (Fisher, Fair Lawn, NJ). Unbiased stereological estimates of the total number and volumetric density of the BrdU-immunoreactive (IR) granule layer cells were obtained by applying the optical fractionator (Luk and Sadikot, 2001) with Stereo Investigator (Microbrightfield, Inc., Colchester, VT) using an Olympus BX40 microscope and Optronix video camera. The rostral and caudal limits of the left dorsal hippocampus were determined as follows: equivalent to Bregma À2.30 mm (where the blades of the dentate gyrus become fully established) to À4.16 mm (when the hippocampus in coronal section contains both unfused dorsal and ventral component) (Paxinos and Watson, 1986) , and every 12 serial section of 40 mm within this volume was examined. Typically, six coronal sections at 480 mm intervals were analyzed throughout the reference volume. Mean section thickness after immunohistochemical processing, mounting, and coverslipping was 14 mm (tissue shrinkage effect), as measured with a z axis microcator. For a given section, the outline of the granule cell layer was traced at 103. Sampling of the dorsal hippocampus granule cell layer was performed by randomly translating a grid with 75 3 75 mm squares onto the section of interest and applying an optical dissector consisting of a 60 3 60 3 10 mm brick. Each section contained 69 to 133 sampling sites, depending on its surface area. Sections were analyzed by using a 1003 lens (oil, numerical aperture of 1.3, with matching condenser). Manual counts (at least one section per animal) confirmed the accuracy of stereological results.
Forced Swim Test
We used the FST as previously described (Porsolt et al., 1977) . Briefly, rats experienced a pretest session followed 24 hr later by a test session. For both the pretest and the test sessions, conducted under low illumination (15 W), the animals were placed in a plastic cylindrical tank (50 cm high by 20 cm in diameter) filled with water at 24 C ± 1 C, with a depth of 40 cm, for which the hindlimbs could not reach the tank floor. In all experiments, the pretest was carried out for 15 min and the test for 5 min in the same tank, but only the last 4 min were analyzed. Prucalopride (2.5 mg/kg, i.p.), RS 67333 (1.5 mg/kg, i.p.), and citalopram (10 mg/kg, i.p.) were administered 30 min before the test session. Following either pretest or test sessions, rats were dried with a towel and kept warm for 30 min before being returned to their home cage.
A camera coupled with a computer recorded animal behavior online during the FST through a specialized digital interface (Videotrack, ViewPoint, Lyon, France). This interface underscored online the subtraction of video frames. Immobility time in FST was derived from the number of frames (every 40 ms) being below a predefined threshold over FST duration. This threshold was preliminarily set up in order to obtain about 95% of the corresponding frames classified as immobile for a nonswimming rat in its water tank. The same threshold was kept constant for naive as well as treated animals. A virtual rectangle was also defined through the use of the interface, corresponding to the space between the surface of water and the upper limit of the cylindrical tank. Climbing behavior was counted as the time spent by the animal in this area. Measurements of locomotion were also performed in order to ensure that the decreased immobility or the increased active behaviors in the FST were not secondary to a nonspecific increase in motor activity produced by the treatments. Thirty minutes after drug administration, rats were placed in activity cages in which photoelectric cells were inserted, allowing recordings of locomotor activity, i.e., quantification of the total number of activity counts (photocell beam breaks) during 10 min session.
Olfactory Bulbectomy and Assessment of Hyperlocomotion
Rats were anesthetized with pentobarbital (40 mg/kg, i.p.) and mounted in a stereotaxic frame. The head was shaved, and a midline sagittal incision was made, extending at least 1 mm to bregma. A burr hole was drilled at points 7 mm anterior to bregma and 2.5 mm either side of the midline at a point corresponding to the posterior margin of the orbit of the eye. After a localized electrical coagulation of the dura and sagittal sinus, olfactory bulbs were removed by suction, and the burr holes were filed with haemostatic sponges. Proviodine was applied to the wound prior to closure using wound clips. In shamoperated animals, the dura and the part of the sagittal sinus above the bulbs were coagulated, but the bulbs were left intact. The animals were given 11 days following surgery to recover prior to minipump insertion and were handled daily to eliminate any aggressiveness that may otherwise arise (Song and Leonard, 2005) .
Minipumps (model 2ML2, specially designed for 2 week treatment) were inserted as described above, and the open-field test was conducted on days 3 and 14 after the implantation (i.e., 14 and 25 days after bulbectomy, respectively). Each rat was placed singly into the center of the open-field apparatus. This apparatus consisted of a square wooden box (85 3 85 cm). Since the effects of OBX on locomotion are much more pronounced in conditions of high illumination (Song and Leonard, 2005) , experiments were conducted with a 75 W bulb positioned 90 cm above the floor of the apparatus. Also, the inner faces of the walls (70 cm high) were covered with aluminum foil. The total distance covered by each animal over a 5 min period was measured by using the same interface as the one used for the FST (Videotrack, ViewPoint, Lyon, France). All experiments were performed between 8:30 and 10:30 a.m.
Sucrose Consumption Test and Chronic Mild Stress Protocol
Animals were first trained to consume a palatable sucrose solution (1.5%). The training lasted 5 weeks. In this period, the sucrose test was made twice a week during the first 3 weeks and once a week during the last 2 weeks. Animals were deprived of food and water 18 hr before the test, which consisted of 1 hr exposure to a bottle with sucrose solution.
On the basis of sucrose intakes in the three final baseline tests, the animals were then divided into two matched groups and placed in separate rooms. One group was exposed to an initial 2 weeks of chronic mild stressors and the other was left undisturbed. The unchallenged group was deprived of food and water for 14 hr before the sucrose consumption test; otherwise, food and water were freely available. The stress procedure was performed according to a procedure optimized in our laboratory (Jayatissa et al., 2006) . Briefly, the protocol consisted of one period of intermittent illumination, stroboscopic light, grouping, food, or water deprivation; two periods of soiled cage and no stress; and three periods of 45 box tilting. During grouping, rats were housed in pairs with different partners alternately being a resident or an intruder. All the stressors lasted from 10 to 14 hr. After the initial 2 weeks of exposure to stress, the unchallenged and stress groups were divided into three matched subgroups and subjected to chronic RS 67333, citalopram, or vehicle administration. Stress was continued during the entire period of treatment, the sucrose consumption test being performed after 3 days of drug administration and then once a week thereafter on days 10, 17, and 24.
Statistical Analysis
The comparison between the two slopes in Figure 2 was performed by using GraphPad Prism software (version 3.03, GraphPad Software Inc.). All other statistics were performed by using one-way ANOVAs, followed by the Tukey's test when multiple comparisons were necessary.
Supplemental Data
The Supplemental Data for this article can be found online at http:// www.neuron.org/cgi/content/full/55/5/712/DC1/. 
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